Safety and Acceptance of Acupuncture and Acupressure in Children, Adolescents, and Young Adults Undergoing Hematopoietic Stem Cell Transplant. Issue 3 (1st May 2023)

• Record Type: Journal Article
• Authors: Bettini, Elizabeth; Idiokitas, Risi; Mahmood, Laila; Jacobs, Shana; Steinhorn, David
• Is Part Of: Cancer nursing. Volume 46:Issue 3(2023)
• Page Start: E204
• Page End: E207
• Publication Date: 2023-05-01
• Subjects: Acupressure -- Acupuncture -- Bone marrow transplant -- Hematopoietic stem cell transplant -- Pediatric Hematology Oncology; Cancer -- Nursing -- Periodicals; 610.736
• DOI: 10.1097/NCC.0000000000001135
• Languages: English
• ISSNs: 0162-220X

Abstract

Abstract : Background: Hematopoietic stem cell transplant (HSCT) is associated with significant morbidity and high symptom burden including mucositis pain, nausea, and vomiting. There is little documentation in the literature regarding acupuncture or acupressure for children undergoing HSCT. Objective: The purpose of this study was to determine the safety and acceptance of acupuncture and acupressure in children undergoing HSCT in a large tertiary care children's hospital. Methods: This is a descriptive retrospective study that evaluated 80 admissions to the HSCT unit over a 24-month period. Every child admitted for HSCT was offered acupuncture or acupressure as part of their care. Results: Of 80 patients, 46 were male patients (ages range, 0-32 years; mean, 8 years). Diagnoses include leukemia/lymphoma, sickle cell disease, aplastic anemia, neuroblastoma, and other metabolic, other solid tumor, or other hematologic disorders. Both allogenic and autologous were represented. Sixty-six patients (82.5%) agreed to treatment with acupuncture, acupressure, or both. There were no adverse effects or safety concerns noted. Symptoms addressed by acupuncture or acupressure included pain from mucositis, nausea, constipation, diarrhea, anxiety, insomnia, and general wellness or healing. Conclusion: This study demonstrates that acupuncture and acupressure are well accepted by children and their families admitted for HSCT and are safe even when performed in the first 4 weeks following transplant when the patient is likely to have thrombocytopenia. Implications for Practice: These findings suggest that there may be more therapies for patients undergoing HSCT to help with symptom control.